An open-label comparative study of 3-hydroxy-3-methylbutyrate between preoperative and postoperative muscle function in osteoarthritic patients with total hip or knee arthroplasty . - HMB-M-OA-HK

yasuda tadashi0 个研究点目标入组 80 人开始时间: 2020年12月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Patients with osteoarthritis who undergo total hip or knee arthroplasty
•2)Patients who will be able to receive standard postoperative rehabilitation
•3)Patients who will be able to receive regular follow-up
•4)Female patients at age 65 and more at the time of consent acquisition
•5)Patients who have voluntarily consented to participate in this study with their comprehension on thorough explanation of this study

•1)Patients who had taken HMB before consent acquisition
•2)Patients who had taken medicine or supplement that may affect muscle function
•3) Patients who are not expected to receive the standard recovery rehabilitation at the recovery phase hospital after transfer from our hospital
•4)Patients with radiotherapy or chemotherapy, or with treatment with steroid or immunosuppressive drugs
•5)Patients with paresis
•6)Patients with history of malignancy within the last 5 years
•7)Patients with history of unstable angina, cardiac infarction, brain infarction, cerebral hemorrhage, or transient cerebral ischemic attack within the last 6 months
•8)Patients with severe diseases in liver, kidney, heart, lung, blood, or endocrine and metabolic systems
•9)Patients with or with history of inflammatory joint diseases except osteoarthritis
•10)Patients with history of total hip or knee arthroplasty within the last 6 months
•11)Patients under consideration of other surgical treatment during the protocol period of this study
•12)Patients participating in other interventional or clinical trial
•13)Patients who are considered inappropriate as the subjects for this study by the principal investigator or co-investigators

发起方

yasuda tadashi